Turnstone Biologics Corp. Share Price

Equities

TSBX

US90042W1009

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 21/06/2024 BST 5-day change 1st Jan Change
2.79 USD +1.82% Intraday chart for Turnstone Biologics Corp. +3.33% +9.63%
Sales 2024 * - Sales 2025 * - Capitalization 64.53M 5.1B
Net income 2024 * -80M -6.33B Net income 2025 * -99M -7.83B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.96 x
P/E ratio 2025 *
-0.93 x
Employees 82
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.17%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.82%
1 week+3.33%
Current month+6.90%
1 month+2.57%
3 months-6.69%
6 months-6.69%
Current year+9.63%
More quotes
1 week
2.64
Extreme 2.64
2.82
1 month
2.54
Extreme 2.54
3.00
Current year
1.80
Extreme 1.8
5.75
1 year
1.63
Extreme 1.625
13.20
3 years
1.63
Extreme 1.625
13.20
5 years
1.63
Extreme 1.625
13.20
10 years
1.63
Extreme 1.625
13.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 30/09/15
Director of Finance/CFO 55 31/01/22
Chief Tech/Sci/R&D Officer 62 28/02/23
Members of the board TitleAgeSince
Director/Board Member 46 30/09/16
Director/Board Member 69 31/12/18
Chief Executive Officer 51 30/09/15
More insiders
Date Price Change Volume
21/06/24 2.79 +1.82% 103,634
20/06/24 2.74 +0.37% 54,447
18/06/24 2.73 +1.11% 54,539
17/06/24 2.7 0.00% 50,122
14/06/24 2.7 -3.57% 48,644

Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm

More quotes
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.79 USD
Average target price
12.67 USD
Spread / Average Target
+354.00%
Consensus